Skip to main content
SpringerLink
Log in

Safety of Medicines: Detection and Reporting Adverse Reactions

  • Chapter
Local Treatment of Inflammatory Joint Diseases

Abstract

This chapter describes the definitions of adverse reactions/events, pharmacovigilance systems, their limitations and basic problems, as well as adverse events connected with radiopharmaceutical agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    In European law instead of ‘drug’, the term ‘medicinal product’ is used.

  2. 2.

    In the USA, the term ‘drug approval’ is used; in Europe the term ‘marketing authorisation’.

References

  1. WHO. The importance of pharmacovigilance, safety monitoring of medicinal products. World Health Organisation, Geneva 2002.

    Google Scholar 

  2. The world medicines situation 2001 – pharmacovigilance and safety of medicines. World Health Organisation, Geneva 2011.

    Google Scholar 

  3. FDA Adverse Event Reporting System (FAERS) (http://www.fda.gov). Glossary of terms used in pharmacovigilance. Glossary11.doc Mar 2011.

  4. Meyboom RHB, Lindquist M, Egberts ACG. An ABC of drug-related problems. Drug Saf. 2000;22(6):415–28.

    Article  CAS  PubMed  Google Scholar 

  5. ICH. E2D guideline post-approval safety data management. Definitions and standards for expedited reporting. Oct 1994. International conferences on harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org.

  6. ICH. E2D guideline clinical safety data management: definitions and standards for expedited reporting. Oct 1994. International conferences on harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org.

  7. Directive 2001/83/EC on the Community code related to medicinal products for human use. REGULATION (EC) No 726/2004 of the EUROPEAN PARLIAMENT and of the COUNCIL of 31 March 2004, laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, as amended, i. e. Regulation (EU) 1235/2010 of the European Parliament and of the Council of December 15, 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) N0 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products. European Commission’s Implementing Regulation (EU) No 520/2012 of 19 June 2012 on the performance of pharmacovigilance activities provided for in Regulation (EC) No 726/2004 of the European Parliament and of the Council and Directive 2001/83/EC of the European Parliament and of the Council, Official Journal of the European Union, 20.6.2012, L 159/5.

    Google Scholar 

  8. EMA/876333/2011. Rev.3* guideline on good pharmacovigilance practices (GVP) Annex I-definitions(Rev.3.) European medicines agency and heads of medicines agencies 2014.

    Google Scholar 

  9. EMA/873138/2011. Guideline on good pharmacovigilance practices (GVP) module VI – management and reporting of adverse reactions to medicinal products (Rev 1).

    Google Scholar 

  10. EMA guideline on good pharmacovigilance practicies (GVP) module IX-signal management. European medicines agency and heads of medicines agencies 2014.

    Google Scholar 

  11. ICH. E2B guideline: periodic benefit-risk evaluation report. Mar 2014. International conferences on harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org.

  12. Report of the Council for International Organisations of Medical Sciences Working group VIII “practical aspects of signal detection in pharmacovigilance”. Geneva: CIOMS; 2010.

    Google Scholar 

  13. EMA guideline on good pharmacovigilance practicies (GVP) module XVI, risk minimisation measures: selection and effectiveness indicators. (Rev. 1.) European medicines agency and heads of of medicines agencies 2014.

    Google Scholar 

  14. Sickmüller B, Thurisch B, Kaszkin-Bettag M. Letter to the editor – proposal for publishing of case reports of adverse drug reactions to authorities by physicians. Glob Adv Health Med. 2013. doi:10.7453/gahmj.2013.007.

    PubMed  PubMed Central  Google Scholar 

  15. ICH. E2B guideline on clinical safety data management: data elements for transmission of individual case safety reports. Feb 2001. International conferences on harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org.

  16. U.S. Department of Health and Human Services. Guidance for industry – good pharmacovigilance practices and pharmacovigilance assessment. (J:/!Guidanc/63590=CC.doc). Mar 2005.

    Google Scholar 

  17. CRF- Code of Federal Regulations Title 21; Part 314 applications for FDA approval to market new drugs. http://www.accessdata.fda.gov.

  18. Advances in FDA’s safety program for marketed drugs, establishing premarket safety review and marketed drug safety as equal priorities at FDA’s center for drug evaluation and research, drug safety center for drug evaluation and research, U.S. Food and Drug Administration U.S. Health and Human Services Report; April 2012.

    Google Scholar 

  19. Sheikholeslam AS. Comparison of EU-Pharmacovigilance system master file (PSMF) with US system. Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels “Master of Drug Regulatory Affairs”. Bonn; 2013.

    Google Scholar 

  20. Aronson JK, Derry S, Loke YK. Adverse drug reactions: keeping up to date. Fundam Clin Pharmacol. 2002;16:49–56.

    Article  CAS  PubMed  Google Scholar 

  21. Zorzela L, Golder S, Liu Y, et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ. 2014;348:f7668. doi:10.1136/bmj.f7668.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS One. 2012;7:e41174. doi:10.1371/journal.pone.0041174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Moher D, Tetzlaff J, Tricco AC, et al. Epidemiology and reporting characteristics of systemic reviews. PLoS Med. 2007;4:447–55.

    Article  Google Scholar 

  24. FDA Adverse Events Reports. http://www.fda.gov.

  25. Pharmakovigilanz. 2014 http://www.BfArM.

  26. Harpaz R, DuMouchel W, LePendu P, et al. Performance of pharmacovigilance signal detection algorithms for FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93. doi:10.1038/clpt.213.24.

  27. Rogers AS, Israel E, Smith CR, et al. Physician knowledge, attitudes and behavior related to reporting adverse drug events. Arch Intern Med. 1988;148:1596–600.

    Article  CAS  PubMed  Google Scholar 

  28. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324:377–84.

    Article  CAS  PubMed  Google Scholar 

  29. Heeley E, Riley J, et al. Prescription-event monitoring and reporting of adverse drug reactions. Lancet. 2001;358:1872–3.

    Article  CAS  PubMed  Google Scholar 

  30. Smith CC, Bennett PM, Pearce HM, et al. Adverse drug reactions in a hospital general medical meriting notification to the Committee of Safety of Medicines. Br J Clin Pharmacol. 1996;42:423–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19:901–10. 1.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Bourgeois FT, Mandl KD, Valim C, Shannon MW. Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics. 2009;124:744–50.

    Article  Google Scholar 

  33. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients. A meta-analysis of prospective studies. JAMA. 1998;279:1200–5.

    Article  CAS  PubMed  Google Scholar 

  34. Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296:1858–66.

    Article  CAS  PubMed  Google Scholar 

  35. Hesse B, Vinberg N, Berthelsen AK, Ballinger JR. Adverse events in nuclear medicine – cause for concern? Eur J Nucl Med Mol Imaging. 2012;39:782–5.

    Article  CAS  PubMed  Google Scholar 

  36. Suleiman OH, Fejka R, Houn F, Walsh M. The radioactive drug research committee: background and retrospective study of reported research data (1975–2004). J Nucl Med. 2006;47:1220–6.

    PubMed  Google Scholar 

  37. Silberstein EB, Ryan J. Prevalence of adverse reactions in nuclear medicine. J Nucl Med 1996;37:185–92. Hesslewood SR, Keeling DH, Radiopharmacy committee of EANM. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med. 1997;24:1179–82.

    Google Scholar 

  38. Hesslewood SR, Keeling DH. Radiopharmacy Committee of the EANM. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med. 1997;24:1179–82.

    CAS  PubMed  Google Scholar 

  39. Santos-Oliveira R. Undesirable events with radiopharmaceuticals. Tohoku J Exp Med. 2009;217:251–7.

    Article  CAS  PubMed  Google Scholar 

  40. Santos-Oliveira R, Smith SW, Carneiro-Leao AMA. Radiopharmaceuticals drug interactions: a critical review. An Acad Bras Cienc. 2008;80:665–75.

    Article  CAS  PubMed  Google Scholar 

  41. Kusakabe K, Okamura T Kassagi K, Komatani A, et al. Subcommittee for safety issues of Radiopharmaceuticals, Medical Science, and Pharmaceutical Committee, Japan Radioisotope Association. The 27th report on survey of the adverse reactions to radiopharmaceuticals (the 30th survey in 2004) Kaku Igaku. 2006;43:23–5.

    Google Scholar 

  42. Siberstein EB. Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011. J Nucl Med. 2014;55:1308–10.

    Article  Google Scholar 

  43. Fischer M, Brinker A. Legal responsibility of the nuclear medicine physician at the radiosynoviorthesis and radionuclide therapy of bone metastases. Der Nuklearmediziner. 2013;36:53–60.

    Article  Google Scholar 

  44. Kisielinski K, Bremer D, Knutsen A, et al. Complications following radiosynoviorthesis in osteoarthritis and arthroplasty: osteonecrosis and intra-articular infection. Joint Bone Spine. 2010;77:252–7.

    Article  PubMed  Google Scholar 

  45. Hennessy S. Disproportionality analyses of spontaneous reports – editorial. Pharmacoepidem Drug Saf. 2004;13:503–4.

    Article  Google Scholar 

  46. Hazel L, Shakir SAW. Under-reporting of adverse drug reactions – a systematic review. Drug Saf. 2006;29:385–96.

    Article  Google Scholar 

  47. Guo JJ, Pandey S, Doyle J, et al. A review of quantitative risk – benefit methodologies for assessing drug safety and efficacy-report of the ISPOR Risk-Benefit Management Working Group. Value Health. 2010;13:657–66.

    Article  PubMed  Google Scholar 

  48. Ioannidis JPA. Adverse events in randomized trials. Arch Intern Med. 2009;169:1737–9.

    Article  PubMed  Google Scholar 

  49. Lis Y, Guo JJ, Roberts MH, et al. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and Outcomes Research Risk Benefit Management Working Group. Value Health. 2012;15:1108–18.

    Article  PubMed  Google Scholar 

  50. Pilkington K, Boshnakova A. Complementary medicine and safety: a systematic investigation of design and reporting of systematic reviews. Complement Ther Med. 2012;20:73–82.

    Article  PubMed  Google Scholar 

  51. American College of Physicians. Improving FDA regulations of prescription drugs. Policy Monograph, Philadelphia; 2009.

    Google Scholar 

  52. Robertson J, Newby DA, Robertson J. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust. 2013;199:684–6.

    Article  PubMed  Google Scholar 

  53. Katamne RA, Jayawardhani. Knowledge, attitude and perception of physicians towards adverse drug reactions (ADR) reporting: a pharmacoepidemiological study. Asian J Pharm Clin Res. 2012;5:210–4.

    Google Scholar 

  54. Iffat W, Shakeel S, et al. Pakistani physicians’ knowledge and attitude towards reporting adverse drug reactions. Afr J Pharm Pharmacol. 2014;8:379–85.

    Google Scholar 

  55. Hudec R, Wilton LV, Kriska M. Comments to regional problems of analgesic risk perception. Bratisl Lek Listy. 2011;12:140–2.

    Google Scholar 

  56. Strom BL. How the US drug safety system should be changed. JAMA. 2006;295:2072–5.

    Article  CAS  PubMed  Google Scholar 

  57. Schnurrer J, Frölich JC. Zur Häufigkeit und Vermeidbarkeit von tödlichen unerwünschten Arzneimittelwirkung. Internist. 2003;44:889–95.

    Article  CAS  PubMed  Google Scholar 

  58. Davies EC, Green CF, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of patient-episodes. PLoS One. 2009;4(2):e4439. doi:10.1371/journal.pone.0004439.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Radiology, Radiation Therapy and Nuclear Medicine, Friedrich-Ebert-Str., D-34117, 55 Kassel, Germany

    Manfred Fischer

  2. Brinker Pharmaconsulting, Stölpchen Weg, D-14109, 37 Berlin, Germany

    Annette Brinker

  3. Bundesverband Pharmazeutischer Industrie, Willemerstrasse, D-63067, 11 Offenbach, Germany

    Barbara Sickmüller

Authors
  1. Manfred Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette Brinker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Sickmüller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Fischer .

Editor information

Editors and Affiliations

  1. Nuklearmedizin Spitalerhof, Hamburg, Germany

    Willm Uwe Kampen

  2. Kassel, Germany

    Manfred Fischer

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fischer, M., Brinker, A., Sickmüller, B. (2015). Safety of Medicines: Detection and Reporting Adverse Reactions. In: Kampen, W., Fischer, M. (eds) Local Treatment of Inflammatory Joint Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-16949-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16949-1_1

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16948-4

  • Online ISBN: 978-3-319-16949-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation